Michael Welsh Email & Phone Number

CSO SiSaf Ltd. Application of nanoparticle drug delivery for human and animal health using SiSaf's nano silicon technology - Bio-Courier®. To be innovative and find new solutions and "fix" problems for drug delivery with a clear focus on commercial applications. To understand specific customer needs and technical challenges to design controlled drug / therapeutic / vaccine delivery formulations addressing drug targeting, solubility, reduced drug toxicity, drug release profile, enhance bioavailability, molecule stabilisation and protection from degradation and optimise formulations to match preferred delivery routes. Over the last several years SiSaf has focused on delivery of nucleic acid using SiSaf Bio-Courier technology with programmes on local and systemic administration of inhibitory RNA molecules.

Veterinary SpeciesVaccine developmentDiagnostic test developmentGovernment and Commercial contract research

Belfast, Antrim, Gb

Postdoctoral Research Fellow Virologist / Immunologist QUB, Department of Veterinary Science, Intervet International (Akzo Nobel) funded research position to investigate the protein antigens of salmon pancreas disease virus (SPDV) to facilitate the development of recombinant DNA-based vaccines. I developed the first diagnostic antibody reagents for the virus and this helped support the development work to control salmon pancreas disease though vaccination.

Post-doctoral position (Viral Vaccine Immunologist) Department of Virology, St Bartholomew’s and the Royal London School of Medicine and Dentistry, London. Funded by British Biotechnology to investigate the protein antigens of varicella-zoster virus (VZV) to facilitate the development of a novel VZV vaccine using the yeast Ty virus-like particle cloning system.

Doctor Of Philosophy (Phd), Immunology / Virology

Bachelor Of Science (Bsc) Honours Degree, Microbiology And Immunology